Severe COVID-19 Recovered Patients do not Display Long-lasting Adaptive Immune Responses

A study revealed that severe COVID-19 patients develop detectable T-cell mediated responses about 3 months after the onset of symptoms and the levels of IgG-specific anti-SARS-CoV-2 antibodies decline over time. The current study was designed to evaluate the specificity and durability of anti- SARS-CoV-2 immune responses in 58 COVID-19 recovered patients who had been hospitalized because of severe COVID-19-related complications.

The patients enrolled in the study had a severe form of COVID-19 with bilateral pneumonia. About 60% of all patients had comorbidities. About 10% and 29% of enrolled COVID-19 recovered patients showed detectable levels of SARS-CoV-2 spike/membrane protein-reactive CD8+ and CD4+ T-cells, respectively, on an average 84 days after the onset of symptoms. The serum samples obtained from 35 patients were analyzed for IgG-specific antibodies developed against the RBD of the viral spike protein. Of these patients, about 60% exhibited detectable levels of SARS-CoV-2-specific antibodies on an average 118 days after the onset of symptoms.

However, the levels of SARS-CoV-2-specific antibodies were found to decline over time in all COVID-19 recovered patients.  The T cell responses become undetectable after 130 days of COVID-19 diagnosis. Interestingly, the presence of comorbidities is found to influence the T cell response but not the antibody response; whereas, disease severity is found to influence the antibody response but not the T cell response. The antibody response showed a declining trend over time. 

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.medrxiv.org/content/10.1101/2021.01.05.20249027v1

#Featured